This work demonstrates that circCRKL is down-regulated in AML, showing potential as a therapeutic target for AML, while it can sponge miR-196a-5p and miR-196b-5p to inhibit p27 expression. The gene discussed is CDKN1B; the disease is acute myeloid leukemia.